Literature DB >> 15615078

Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.

P Garnero1, P D Delmas.   

Abstract

In osteoporosis, the main cause for concern is the increase in the risk of fractures. The level of bone mineral density (BMD) measured by various techniques has been shown to be a strong predictor of fracture risk in postmenopausal women. However, half of patients with incident fractures have BMD value above the diagnostic threshold of osteoporosis defined as a T-score of -2.5 SD or more below the average value of young healthy women. Clearly there is a need for improvement in the identification of patients at risk for fracture. Several prospective studies have shown that an increased bone resorption evaluated by specific biochemical markers was associated with increased risk of the hip, spine and non-vertebral fractures independently of BMD. The use of bone markers in individual patients may be appropriate in some situations, especially in women who are not detected at risk by BMD measurements. For example, in the OFELY study including 668 postmenopausal women followed prospectively over 9 years, we found that among the 115 incident fractures, 54 (47%) actually occurred in non-osteoporotic women. Among these women, the combination of bone markers and history of previous fracture was highly predictive of fracture risk. Thus, bone markers may be used in the assessment of fracture risk in selected cases in which BMD and clinical risk factors are not enough to take a treatment decision. Advances in our knowledge of bone matrix biochemistry, most notably of post-translational modifications in type I collagen, may allow identification of biochemical markers that reflect changes in the material property of bone, which is an important determinant of bone strength. Preliminary in vitro studies indicate that the extent of post-translational modifications of collagen--which can be reflected in vivo by the measurement of the urinary ratio between native and isomerised type I collagen--play a role in determining the mechanical competence of cortical bone, independently of BMD. Further studies in osteoporosis should explore the changes in these biochemical parameters of bone matrix as they may represent a key component of bone quality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615078

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN: 1108-7161            Impact factor:   2.041


  44 in total

1.  Differential effects of calcium- and vitamin D-fortified milk with FOS-inulin compared to regular milk, on bone biomarkers in Chinese pre- and postmenopausal women.

Authors:  Marlena C Kruger; Yoke Mun Chan; Barbara Kuhn-Sherlock; Lee Ting Lau; ChinChin Lau; Y S Chin; Joanne M Todd; Linda M Schollum
Journal:  Eur J Nutr       Date:  2015-08-12       Impact factor: 5.614

2.  Dynamic Fluid Flow Mechanical Stimulation Modulates Bone Marrow Mesenchymal Stem Cells.

Authors:  Minyi Hu; Robbin Yeh; Michelle Lien; Morgan Teeratananon; Kunal Agarwal; Yi-Xian Qin
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

Review 3.  Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.

Authors:  Serge Cremers; Patrick Garnero
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice.

Authors:  D J Leeming; P Alexandersen; M A Karsdal; P Qvist; S Schaller; L B Tankó
Journal:  Eur J Clin Pharmacol       Date:  2006-08-16       Impact factor: 2.953

Review 5.  Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents.

Authors:  E Seeman
Journal:  Osteoporos Int       Date:  2007-02-17       Impact factor: 4.507

Review 6.  Is bone quality associated with collagen age?

Authors:  D J Leeming; K Henriksen; I Byrjalsen; P Qvist; S H Madsen; P Garnero; M A Karsdal
Journal:  Osteoporos Int       Date:  2009-03-28       Impact factor: 4.507

7.  Effect of monthly ibandronate on hip structural geometry in men with low bone density.

Authors:  H K Genant; E M Lewiecki; T Fuerst; M Fries
Journal:  Osteoporos Int       Date:  2011-08-03       Impact factor: 4.507

Review 8.  Bone markers in osteoporosis.

Authors:  Patrick Garnero
Journal:  Curr Osteoporos Rep       Date:  2009-09       Impact factor: 5.096

9.  Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study.

Authors:  T W Weiss; E S Siris; E Barrett-Connor; P D Miller; C A McHorney
Journal:  Osteoporos Int       Date:  2007-06-19       Impact factor: 4.507

10.  Combining bone resorption markers and heel quantitative ultrasound to discriminate between fracture cases and controls.

Authors:  D Nanchen; J Cornuz; C Ruffieux; W Riesen; P Burckhardt; M A Krieg
Journal:  Osteoporos Int       Date:  2009-01-31       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.